Patents Assigned to T Cell Sciences, Inc.
-
Patent number: 5976540Abstract: The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.Type: GrantFiled: April 16, 1998Date of Patent: November 2, 1999Assignee: T Cell Sciences, Inc.Inventors: Charles W. Rittershaus, Carol A. Toth
-
Patent number: 5858969Abstract: Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid:mannose molar ratio of .gtoreq.0.25.Type: GrantFiled: June 6, 1995Date of Patent: January 12, 1999Assignee: T Cell Sciences, Inc.Inventors: Henry C. Marsh, Jr., Richard A.G. Smith, Chang-Jing Grace Yeh, John Lifter, Anne Mary Freeman, Michael L. Gosselin
-
Patent number: 5856297Abstract: Human complement receptor type 1 (CR1). Nucleic acid molecules encoding full-length CR1 protein and fragments thereof having complement regulatory activity are described, as well as recombinant CR1 protein and polypeptides, vectors for their expression, and cell lines expressing or bearing DNA molecules encoding such proteins and polypeptides, including a soluble CR1 polypeptide consisting of the extracellular 30 short consensus repeat domains of the mature CR1 protein. The nucleic acids and polypeptides described are useful in diagnosis and treatment of disorders involving complement activity and inflammation. Compositions useful in therapeutic applications are also disclosed.Type: GrantFiled: June 6, 1995Date of Patent: January 5, 1999Assignees: The Johns Hopkins University, Brigham & Women's Hospital, T Cell Sciences, Inc.Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas C. Makrides, Henry C. Marsh, Jr.
-
Patent number: 5856300Abstract: The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type I, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Louis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.Type: GrantFiled: November 13, 1995Date of Patent: January 5, 1999Assignee: T Cell Sciences, Inc.Inventors: Charles W. Rittershaus, Carol A. Toth
-
Patent number: 5840858Abstract: This invention relates to the application of immobilized metal affinity chromatography to the purification of complement receptor proteins.Type: GrantFiled: April 3, 1996Date of Patent: November 24, 1998Assignee: T Cell Sciences, Inc.Inventors: Thomas Michael Smith, Gail Folena-Wasserman
-
Patent number: 5808109Abstract: The present invention is directed to compounds which suppress immune responses and/or selectively inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the pharmaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activities, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.Type: GrantFiled: June 7, 1995Date of Patent: September 15, 1998Assignees: T Cell Sciences, Inc., The University of MississippiInventors: Robert D. Sindelar, Barton J. Bradbury, Teodoro S. Kaufman, Stephen H. Ip, Henry C. Marsh, Jr., Chew Lee
-
Patent number: 5656659Abstract: The present invention is directed to compounds which suppress immune responses and/or selectivly inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the phamaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activites, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.Type: GrantFiled: November 18, 1994Date of Patent: August 12, 1997Assignees: T Cell Sciences, Inc., The University of MississippiInventors: Robert D. Sindelar, Barton J. Bradbury, Teodoro Saul Kaufman, Stephen Hoi-Chuen Ip, Henry Clinton Marsh, Jr., Chew Lee
-
Patent number: 5601822Abstract: The present invention provides purified polypeptides which comprise at least a portion of a .delta. T cell receptor polypeptide, a .gamma. T cell receptor polypeptide, a .gamma., .delta. T cell receptor complex or a .gamma., .gamma. T cell receptor complex. Substances capable of forming complexes with these polypeptides are also provided.Additionally, methods for detecting T cells which have within them or on their surfaces a polypeptide of the present invention are provided. Moreover, methods for diagnosing immune system abnormalities are provided which comprise measuring in a sample from a subject the number of T cells which have within them or on their surfaces a polypeptide of the present invention.Type: GrantFiled: November 19, 1993Date of Patent: February 11, 1997Assignees: T Cell Sciences, Inc., President and Fellows of Harvard College, Dana Farber Cancer InstituteInventors: Michael B. Brenner, Jack L. Strominger, Johnathan Seidman, Stephen H. Ip, Michael S. Krangel
-
Patent number: 5552300Abstract: The present invention relates to the production of full length T cell antigen receptor V region proteins. The invention provides for methods of expressing the proteins as well as expression vectors for enhanced production of V region proteins. The invention further provides for the V.beta.5.3 region protein. The proteins of the invention have uses in the diagnosis and therapy of immune disorders.Type: GrantFiled: January 13, 1994Date of Patent: September 3, 1996Assignee: T Cell Sciences, Inc.Inventors: Savvas C. Makrides, Patrick C. Kung
-
Patent number: 5506247Abstract: The present invention is directed to compounds which suppress immune responses and/or selectively inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the pharmaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activities, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.Type: GrantFiled: January 21, 1994Date of Patent: April 9, 1996Assignees: T Cell Sciences, Inc., The University of MississippiInventors: Robert D. Sindelar, Barton J. Bradbury, Teodoro S. Kaufman, Stephen H. Ip, Henry C. Marsh, Jr., Chew Lee
-
Patent number: 5472939Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.Type: GrantFiled: October 19, 1993Date of Patent: December 5, 1995Assignees: The Johns Hopkins University, The Brigham and Women's Hospital, T Cell Sciences, Inc.Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas C. Makrides, Henry C. Marsh, Jr.
-
Patent number: 5456909Abstract: The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders involving inflammation and inappropriate complement activation and in thrombotic or shock state conditions. The invention provides novel glycoforms and methods for producing, detecting, enriching and purifying such glycoforms. The invention further provides methods of specifically producing a glycoform by recombinant or chemical means. Preferred embodiments of the invention include sialylated glycoforms and glycoforms with a pI.ltoreq.5.1 determined by chromatofocusing or with a sialic acid to mannose molar ratio of >0.25. The glycoforms may be formulated alone in therapeutic compositions or in combination with thrombolytic agents.Type: GrantFiled: August 7, 1992Date of Patent: October 10, 1995Assignees: T Cell Sciences, Inc., SmithKline Beecham p.l.c.Inventors: Henry C. Marsh, Jr., Richard A. G. Smith, Chang-Jing G. Yeh, John Lifter, Anne M. Freeman, Michael L. Gosselin
-
Patent number: 5436319Abstract: Cell-free or released T cell antigen receptors, immunoassays which allow the detection of the released T cell antigen receptor in cell culture supernatants, cell lysates, and biological fluids, as well as diagnostic and therapeutic compositions and methods for monitoring and treating certain diseases or disorders which elicit or involve a T cell response are described. The released T cell antigen receptors described herein differ from the cell membrane bound antigen receptors and appear to exist in a variety of forms, some of which may be complexed with other T cell determinants such as the T3 antigen. Despite the size heterogeneity of the released T cell antigen receptors or receptor/complexes, these may be reliably identified using anti-receptor antibodies, including, but not limited to, anti-major framework, anti-minor frarmework and anti-clonotypic antibodies which define particular epitopes of the released T cell receptor or receptor/complex.Type: GrantFiled: September 26, 1994Date of Patent: July 25, 1995Assignee: T Cell Sciences, Inc.Inventors: Patrick C. Kung, Stephen H. Ip, Michael C. Brown
-
Patent number: 5401767Abstract: The present invention is directed to compounds which suppress immune responses and/or selectively inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the pharmaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activities, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.Type: GrantFiled: December 21, 1992Date of Patent: March 28, 1995Assignees: T Cell Sciences, Inc., The University of MississippiInventors: Robert D. Sindelar, Barton J. Bradbury, Teodoro Kaufman, Stephen H. Ip, Henry C. Marsh, Jr.
-
Patent number: 5366986Abstract: The present invention is directed to compounds which suppress immune responses and/or selectively inhibit complement. These compounds contain an aromatic ring and are substituted dihydrobenzofurans, spirobenzofuran-2(3H)-cycloalkanes, and their open chain intermediates. The compounds of the present invention, and the phamaceutically acceptable salts thereof, interrupt the proteolytic processing of C5 to bioactive components, exhibit immunosuppressive activites, and have therapeutic utility in the amelioration of disease and disorders mediated by complement and/or immune activity.Type: GrantFiled: December 6, 1990Date of Patent: November 22, 1994Assignees: T Cell Sciences, Inc., The University of MississippiInventors: Robert D. Sindelar, Barton J. Bradbury, Teodoro S. Kaufman, Stephen H. Ip, Henry C. Marsh, Jr., Chew Lee
-
Patent number: 5340921Abstract: The present invention provides purified polypeptides which comprise at least a portion of a .delta.T cell receptor polypeptide, a .gamma.T cell receptor polypeptide, a .gamma., .delta.T cell receptor complex or a .gamma., .gamma.T cell receptor complex. Substances capable of forming complexes with these polypeptides are also provided.Additionally, methods for detecting T cells which have within them or on their surfaces a polypeptide of the present invention are provided. Moreover, methods for diagnosing immune system abnormalities are provided which comprise measuring in a sample from a subject the number of T cells which have within them or on their surfaces a polypeptide of the present invention.Type: GrantFiled: February 19, 1987Date of Patent: August 23, 1994Assignees: T Cell Sciences, Inc., The Dana-Farber Cancer Institute, President & Fellows of Harvard CollegeInventors: Michael B. Brenner, Jack L. Strominger, Johnathan Seidman, Stephen H. Ip, Michael S. Krangel
-
Patent number: 5256642Abstract: The present invention relates to compositions comprising soluble complement receptor 1 (CR1) and a thrombolytic agent. In a specific embodiment, the thrombolytic agent is anisoylated human plasminogen-streptokinase activator complex (ASPAC). The invention further relates to methods for treating thrombotic conditions in humans and animals by administering a composition comprising soluble CR1 and a thrombolytic agent. In particular, the compositions and methods are useful both for reducing reperfusion injury and ameliorating the other effects of myocardial infarction.Type: GrantFiled: September 24, 1990Date of Patent: October 26, 1993Assignees: The Johns Hopkins University, Brigham and Women's Hospital, T Cell Sciences, Inc.Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas Makrides, Henry C. Marsh, Jr.
-
Patent number: 5223426Abstract: The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed .alpha.F1 and .alpha.F2, which react with two different epitopes on the framework region of the .alpha. monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with .beta. chain variable regions V.beta.5.3 and V.beta.8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody .delta.Type: GrantFiled: December 11, 1989Date of Patent: June 29, 1993Assignee: T Cell Sciences, Inc.Inventors: Robert V. Skibbens, Larry D. Henry, Charles W. Rittershaus, Wei-Tao Tian, Stephen H. Ip, Patrick C. Kung, Mary Ellen Snider, Jone-Long Ko, Nancy L. Wood
-
Patent number: 5212071Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.Type: GrantFiled: April 3, 1989Date of Patent: May 18, 1993Assignees: The Johns Hopkins University, Brigham and Women's Hospital, T Cell Sciences, Inc.Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas C. Makrides
-
Patent number: 5185250Abstract: The present invention is directed to purified polypeptides comprising the .gamma. T cell antigen receptor (TCR) polypeptide, the .delta. TCR polypeptide, a .gamma., .delta. TCR complex, or a fragment thereof containing an epitope. The invention also relates to nucleic acid sequences encoding such polypeptides, and subsequences thereof. In specific embodiments, the invention relates to nucleic acid sequences comprising variable, diversity, joining, or constant regions of the .delta. TCR gene sequence. The invention also relates to monoclonal antibodies specifically reactive with an epitope of the gamma or delta TCR polypeptides. In specific embodiments, these antibodies are reactive with the delta constant region, the delta variable region, or gamma constant region. Such antibodies can be identified by detecting co-modulation of the CD3 antigen. In another embodiment, the invention relates to compositions comprising substantially purified cells which express both a .gamma., .delta. TCR and the CD4 antigen.Type: GrantFiled: January 13, 1989Date of Patent: February 9, 1993Assignees: T Cell Sciences, Inc., Dana Farber Cancer Institute, President & Fellows of Harvard CollegeInventors: Michael B. Brenner, Jonathan Seidman, Jack L. Strominger, Stephen H. Ip, Michael S. Krangel, Hamid Band